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Introduction {#sec1}
============

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative condition characterized by a progressive loss of upper and lower MNs ([@bib45]). There is no cure to halt or reverse the degeneration and the median patient survival is 3--5 years ([@bib37]). Approximately 20% of ALS cases are familial with mutations identified in greater than 20 genes across diverse cellular functions ([@bib2], [@bib41]). Several mutations in the superoxide dismutase 1 (*SOD1*) gene have been linked to ALS ([@bib1]). Although rodent models of ALS have provided valuable insights into disease pathophysiology, the relevance of these findings to human ALS has been questioned due to the inherent species-specific differences as well as the fact that most rodent models overexpress the mutant proteins at non-physiological levels ([@bib12]). Spinal motor neurons (MNs) differentiated from patient-specific induced pluripotent stem cells (iPSCs) have provided researchers with access to human MNs bearing ALS-associated mutations in the context of the patient\'s genetic background, thereby providing a powerful in vitro human model of disease that can complement existing transgenic rodent models ([@bib9]). In this study, we used patient-derived iPSCs bearing the SOD1 E100G mutation combined with genome engineering, neuronal differentiation, and genomics to identify pathways dysregulated in ALS. More importantly, we demonstrate that modulation of these pathways by pharmacological intervention results in a reduction of disease-phenotypic severity.

Results {#sec2}
=======

Disease modeling using iPSCs can be confounded by phenotypic variation resulting from genetic differences between individual iPSC lines ([@bib31]). To overcome this obstacle, we sought to generate isogenic cell lines by targeted correction of the point mutation in the *SOD1* iPSC using the CRISPR-Cas9 system ([@bib15]). We designed a guide RNA to specifically target the mutant allele, taking advantage of the observation that the A \> G mutation in the *SOD1* locus creates a PAM recognition sequence not present in the reference allele ([Figure 1](#fig1){ref-type="fig"}A). In addition, the guide RNA was chosen such that Cas9 would create a double-stranded break within 5--6 bp of the targeted mutation, thereby increasing the efficiency of incorporating the reference allele provided via a donor DNA oligonucleotide ([Figure 1](#fig1){ref-type="fig"}A and [Experimental Procedures](#sec4){ref-type="sec"}). Correction of the heterozygous point mutation in the *SOD1* gene was confirmed by PCR amplification of the targeted genomic regions followed by capillary sequencing ([Figure 1](#fig1){ref-type="fig"}B). In addition, the corrected iPSCs displayed a normal karyotype ([Figure S1](#mmc1){ref-type="supplementary-material"}A).

We differentiated the diseased and corrected iPSCs as well as an iPSC line derived from a healthy individual (designated as 80a) into spinal motor neurons by adapting a recently published protocol capable of generating MNs with high efficiency ([Figure 1](#fig1){ref-type="fig"}C; [@bib30]). For all the iPSC lines used in our study, we were able to generate OLIG2+ motor neuron progenitors at day 10 and post-mitotic ISL1+/TUJ1+ MNs at day 14 ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). At day 30 of differentiation, all iPSC lines generated ISL1+/TUJ1+ spinal MNs with efficiencies \>70%, similar to that observed previously ([Figure 1](#fig1){ref-type="fig"}D). In addition, greater than 80% of the ISL1+ MNs at day 30 also expressed CHAT, a marker of mature MNs, and both ISL1+ MNs as well as ISL1− non-MNs expressed MAP2, a pan-neuronal marker expressed in mature neurons ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}D; [@bib38]). Further, our iPSC-derived MNs were electrophysiologically active and responded to optogenetic stimulation ([Figure 1](#fig1){ref-type="fig"}F). Lastly, when co-cultured with rat cortical neurons ([Figure S1](#mmc1){ref-type="supplementary-material"}E), MNs displayed synchronized neural activity as measured by the genetically encoded Ca+ indicator GCaMP6 ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Importantly, the observed MN neural activity was synchronous with the cortical neuronal activity ([Figure S1](#mmc1){ref-type="supplementary-material"}G), indicating that our MNs were capable of accepting synaptic input from the cortical neurons. Taken together, the marker expression and neural activity indicated that our iPSC-derived MNs were mature and functionally active.

Since the over-arching phenotype observed in ALS patients is the specific loss of MNs, we asked whether ALS MNs would reveal disease-associated decline of survival in vitro. ALS is an adult-onset disease, therefore we monitored survival of MNs after they had attained maturity. Accordingly, we followed MN survival in low-density cultures from day 30 to day 44 ([Figure 2](#fig2){ref-type="fig"}A). ALS mutant MNs showed a significant decline in survival compared with the healthy control MNs ([Figure 2](#fig2){ref-type="fig"}B). On the other hand, genetic correction of the disease MNs significantly improved survival to a level comparable with wild-type MNs, indicating that correction of the mutation had ameliorated the disease phenotype ([Figure 2](#fig2){ref-type="fig"}B). Importantly, this decline in survival was not observed in ISL1−/TUJ1+ non-MN ([Figure 2](#fig2){ref-type="fig"}C), thereby recapitulating the MN-specific loss observed in ALS. In addition, we observed increased cleaved caspase activity in disease MN cultures (day 37) compared with healthy or isogenic control cultures, indicating that the loss of diseased MNs was, in part, due to apoptosis ([Figure 2](#fig2){ref-type="fig"}D).

We observed that increased apoptosis in diseased MNs was also accompanied by morphological changes that were consistent with observations of postmortem spinal tissue from ALS patients ([@bib21]). Morphometric analysis of our in vitro ALS model revealed a reduction in the soma size, maximum neurite length, as well as average neurite tree length in mutant MNs at day 44 compared with the control MNs, while genetic correction of the mutation improved these morphological characteristics in the isogenic MNs ([Figures 2](#fig2){ref-type="fig"}E--2G). We also observed significantly higher levels of the tumor suppressor p53 (TP53) in the nuclei of mutant SOD1 MNs compared with both the healthy control and isogenic MNs ([Figure 2](#fig2){ref-type="fig"}H), which is concordant with activated p53 observed in ALS postmortem spinal tissue as well as rodent models of ALS ([@bib35], [@bib36]). Studies on the SOD1 G93A mouse model of ALS, as well as a recent iPSC model of SOD1 ALS, have revealed heightened endoplasmic reticulum (ER) stress in ALS MNs ([@bib22], [@bib34]). In cells undergoing ER stress, IRE1 splices XBP1 to generate the active spliced form of the transcription factor (sXBP1), while PERK activates the transcription factor ATF4, which leads to upregulation of ATF3 and CHOP ([@bib17], [@bib48]). To assay whether our in vitro model revealed an increase in ALS-related ER stress, we measured the ratio of spliced *XBP1* to total *XBP1* transcript levels (*sXBP1:XBP1*) via qRT-PCR. We found an increased *sXBP1:XBP1* ratio in SOD1 MNs compared with the control MNs that normalized upon genetic correction ([Figure 2](#fig2){ref-type="fig"}I). In addition, we observed significantly higher levels of ATF3 and CHOP in SOD1 MN cultures compared with both the control and isogenic MNs ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B), indicating that the ALS iPSC-derived MNs displayed an increased ER stress response.

The observed correction of the phenotypes was not due to altered expression of *SOD1* transcripts between the diseased and isogenic MNs ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Aggregation of mutant SOD1 into insoluble inclusions is commonly observed in SOD1 ALS ([@bib44]). Treatment of MN cultures with the proteasome inhibitor MG132 revealed significant levels of insoluble SOD1 in the diseased MNs, although similar levels of soluble SOD1 protein were observed between the diseased and isogenic controls ([Figure 2](#fig2){ref-type="fig"}J). Interestingly, an extra band that migrated slightly faster was detected for SOD1 specifically in the mutant MN soluble fraction, probably representing misfolded protein ([@bib4]). Taken together, the phenotypes observed in our in vitro model closely recapitulate findings from ALS postmortem tissue and rodent models. In addition, amelioration of the phenotypes upon genetic correction indicated that the observed phenotypes resulted from the underlying mutation and were not due to genotypic variations between the iPSC lines.

To understand the molecular pathways driving MN loss, we performed genome-wide transcriptome profiling of the diseased and corrected MNs using RNA-seq. We chose to use young MNs (day 30) to avoid transcriptional changes associated with cell death. Unsupervised hierarchical clustering of the RNA-seq data showed that the diseased MNs segregated distinctly from the corrected ones, indicating that correction of the SOD1 mutant allele had induced significant changes in the transcriptome ([Figure 3](#fig3){ref-type="fig"}A). We identified 480 genes in the SOD1 dataset that were differentially regulated (p \< 0.01) with a majority of the genes being activated in SOD1 mutant MNs ([Figure 3](#fig3){ref-type="fig"}A). To enable sensitive detection of altered regulatory pathways from the differential gene expression data, we performed gene set enrichment analysis (GSEA), which relies on ranking genes in order of significance and avoids setting hard thresholds to identify differentially expressed genes ([@bib32], [@bib42]).

GSEA identified several pathways as differentially regulated in ALS MNs. For SOD1, significantly upregulated pathways were associated with p53 activation, cell-cycle regulation, WNT signaling, AP1 activation, and the unfolded protein response (UPR) ([Figure 3](#fig3){ref-type="fig"}B). Strikingly, the downregulated gene sets were associated with mitochondrial function, including electron transport, ATP synthesis, and oxidative phosphorylation ([Figure 3](#fig3){ref-type="fig"}B). Mitochondrial defects and an activated UPR have previously been shown to be associated with the SOD1 A4V mutation in MNs ([@bib22]). Here, we find that the SOD1 E100G mutation results in similar molecular defects in MNs. In addition, genes involved in ion channel transport, especially γ-aminobutyric acid receptors, were also downregulated, which could partially explain the previously reported excitotoxicity in SOD1 MNs ([@bib47]) ([Figure 3](#fig3){ref-type="fig"}B).

For further investigation, we decided to focus on the pathways that were activated in ALS MNs. qRT-PCR confirmed differential expression of several genes identified from RNA-seq analysis and representative of pathways found to be activated by GSEA ([Figure 3](#fig3){ref-type="fig"}C). We hypothesized that the activation of seemingly disparate pathways in mutant SOD1 MNs could result from the differential activation of a few upstream effectors. When placed in the context of a functional gene network, we observed that several of these pathways shared functional interactions with MAPK signaling and displayed extensive cross-talk between the identified pathways ([Figure 3](#fig3){ref-type="fig"}D). For example, the AP1 complex protein JUN can be directly activated by the ERK (MAPK1,3), JNK (MAPK8,9), and p38 (MAPK14) kinases, while the WNT mediator CTNNB1 (β-catenin) can be activated by the p38 (MAPK14) kinase. In addition, JUN as well as the cell-cycle mediators CDK1 and CDK2 have functional interactions with TP53 ([Figure 3](#fig3){ref-type="fig"}D). The network analysis raised the possibility that activation of a select few pathways may be sufficient to initiate the cascade of signaling perturbations observed from our RNA-seq data.

To investigate whether the activated pathways identified in ALS MNs were causal or merely associated with the disease phenotype, we assayed MN survival in vitro after pharmacological inhibition of the identified pathways. MNs differentiated from mutant SOD1 iPSCs were treated with small-molecule inhibitors targeting the p38, ERK, JNK, and CDK kinases, as well as p53 and WNT pathways, at the indicated concentrations starting at day 30 and continued until day 44 ([Figure 4](#fig4){ref-type="fig"}A, [Table S1](#mmc1){ref-type="supplementary-material"}). Untreated (vehicle only control) SOD1 MNs showed a significant loss of survival with ∼50% of the MNs lost at day 44 compared with day 30 ([Figure 4](#fig4){ref-type="fig"}A). Strikingly, inhibition of the AP1 complex, especially via targeting ERK signaling, reduced MN loss in a dose-dependent manner such that only 16% of the MNs were lost at day 44 at the highest concentration used ([Figure 4](#fig4){ref-type="fig"}A). Inhibition of p38/MAPK signaling similarly restricted mutant SOD1 MN loss to 25% ([Figure 4](#fig4){ref-type="fig"}A). Treatment of SOD1 MNs with a JNK inhibitor or an inhibitor of the WNT pathway had a significant but modest effect on SOD1 MN survival compared with the control treatment ([Figure 4](#fig4){ref-type="fig"}A). Surprisingly, inhibition of the p53 pathway displayed only a modest improvement on the survival of ALS MNs, suggesting that p53 activation may play a minor role in driving neurodegeneration in ALS ([Figure 4](#fig4){ref-type="fig"}A). The CDK inhibitor did not promote survival of ALS MNs and, unexpectedly, was toxic to MNs at the higher concentrations used ([Figure 4](#fig4){ref-type="fig"}A). In concordance with our phenotypic screen, we observed activation of ERK1/2 and JNK1/2 in the SOD1 mutant MNs ([Figure 4](#fig4){ref-type="fig"}B). Surprisingly, contrary to our expectation, we did not observe activation of p38 in mutant SOD1 MNs compared with isogenic control MNs ([Figure 4](#fig4){ref-type="fig"}B).

We performed immunofluorescence assays in ALS and isogenic control MNs to confirm activation of the AP1 and WNT pathways. For a given target protein (i.e., JUN), we measured the median fluorescent signal in the nuclei of diseased and isogenic control MNs and plotted the distribution of intensities ([Figure 4](#fig4){ref-type="fig"}C). Immunofluorescence assays confirmed increased nuclear localization of the AP1 complex member JUN as well as β-catenin in mutant SOD1 MNs compared with the isogenic control MNs ([Figures 4](#fig4){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}A), confirming activation of the AP1 and WNT pathways in ALS MNs.

ALS is characterized by selective loss of MNs, while other neurons remain viable even though they harbor the same germline mutations. Using our in vitro model, we asked if there was differential activation of signaling pathways in MNs and non-MNs that might confer disease-specific loss of MNs. We analyzed nuclear localization of JUN and β-catenin in MNs (ISL1+) and non-MNs (ISL1−). Strikingly, we found that the levels of nuclear JUN were almost five times higher in MNs compared with non-MNs ([Figure 4](#fig4){ref-type="fig"}D). This difference between MNs and non-MNs was evident even in the isogenic controls and was heightened in the SOD1 cultures ([Figure 4](#fig4){ref-type="fig"}D). This observation suggests a mechanism where MNs require an active but tightly regulated AP1 pathway for normal homeostasis that is not required by non-MNs. Mutant SOD1 might cause hyperactivation of the AP1 pathway via ERK and JNK activation, perturbing the homeostasis and thereby driving neurodegeneration ([Figure 4](#fig4){ref-type="fig"}E). Although we observed a modest increase in nuclear JUN in the non-MN population, the absolute levels of the protein might not be sufficient to perturb homeostasis. This might explain the selective loss of MNs due to over-activation of the AP1 pathway. We observed a similar trend for WNT activation, where MNs displayed higher WNT activity compared with non-MNs, although the difference was less striking compared with that observed for JUN ([Figure S3](#mmc1){ref-type="supplementary-material"}B).

Next, we asked whether pathways driving neurodegeneration in SOD1 MNs were also activated by other ALS-associated mutations. To answer this question, we sought to analyze the MAPK pathway in MNs bearing mutations in the FUS gene. We obtained iPSCs from a patient homozygous for the recessive H517Q mutation in the *FUS* gene ([@bib24]) and corrected this recessive mutation to heterozygous wild-type using the CRISPR-Cas9 system. Correction of the homozygous point mutation was confirmed by PCR amplification of the targeted genomic region followed by DNA sequencing ([Figure 5](#fig5){ref-type="fig"}A). We further confirmed that the corrected FUS iPSCs displayed a normal karyotype ([Figure 5](#fig5){ref-type="fig"}B). We were able to differentiate both the mutant and corrected FUS iPSCs into ISL1+/TUJ1+ spinal MNs with efficiencies similar to those obtained with the SOD1 iPSCs (H517Q/H517Q, 73% ± 1.7%; +/H517Q, 70% ± 0.74%; mean ± SEM) ([Figure 5](#fig5){ref-type="fig"}C). In addition, greater than 85% of ISL1+ MNs (day 30) expressed the mature MN marker CHAT ([Figure 5](#fig5){ref-type="fig"}C), similar to efficiencies obtained using SOD1 and control iPSCs. To investigate activation of the MAPK pathway, we assayed expression of individual MAPK family members in protein lysates derived from the mutant and corrected FUS MNs. Strikingly, we found activation of the p38 kinase and ERK kinase in the FUS mutant MNs, while the JNK kinase was not activated ([Figure 5](#fig5){ref-type="fig"}D). These observations indicate that MAPK activation is a common feature related to both SOD1 and FUS mutations, although these mutations activate distinct members of the MAPK family.

Discussion {#sec3}
==========

Although animal models have provided valuable mechanistic insights into the pathophysiology of ALS, there has been a lack of success in translating these findings to therapies ([@bib12]). This is perhaps due to species-specific differences between humans and rodents, or because there are issues with the animal model itself where a phenotype is observed only when the mutant protein is overexpressed at non-physiological levels. The use of patient-derived iPSCs promises to circumvent some of these obstacles by providing human neurons expressing the mutant protein at physiological levels in the relevant genetic background. However, one of the caveats of iPSC-based disease modeling is the phenotypic variation observed due to the underlying genetic differences between different iPSC lines. In addition, since iPSC-derived neurons are considered to be fetal-like ([@bib38]), it is important to establish that the in vitro model is capable of recapitulating disease phenotypes observed in ALS patients.

To exclude the possibility of observing phenotypic differences due to genetic variation in the iPSC lines, we generated isogenic iPSC lines by correcting the point mutation in the *SOD1* genomic locus using CRISPR-Cas9 genome editing technology. Next, we confirmed the maturity of our iPSC-derived neuronal cultures by assaying for expression of CHAT and MAP2, bona fide markers of MN maturity. Further, by assaying for phenotypes that were observed in either ALS postmortem tissue or rodent models, we established that our in vitro model faithfully recapitulates specific aspects of the disease.

Having established that we were able to capture ALS disease pathophysiology in our in vitro system, we sought to uncover additional pathways dysregulated in ALS MN by deep RNA-seq. Analysis of the RNA-seq data identified several pathways commonly dysregulated in ALS MNs. For instance, activation of cell-cycle genes and p53 was observed in mutant SOD1 MNs. Since neurons are post-mitotic, reactivation of the cell cycle in neurons results in activation of the apoptotic pathway, partly in a p53-dependent manner ([@bib16]). Hence, we expected that inhibition of either p53 or the cell-cycle program would result in increased survivability of ALS MNs. However, inhibition of the cell-cycle pathway by targeting the CDK proteins diminished cell survival. This suggests that CDKs may have cell-cycle-independent functions in MN essential for homeostasis. Inhibition of p53 resulted in a modest improvement in survival, indicating that p53 may not be a driver of neurodegeneration, an observation supported by rodent ALS models ([@bib23]).

On the other hand, pharmacological inhibition of MAPK signaling significantly improved survival for mutant SOD1 MN. In addition, we observed activation of ERK and JNK kinases in addition to JUN, an AP1 complex member and a direct target of both ERK and JNK signaling. It must be noted that mutant SOD1 MNs responded favorably to ERK inhibition but only modestly to JNK inhibition. Even though p38 kinase was not observed to be activated in SOD1 MNs compared with control, inhibition of p38/MAPK significantly improved mutant SOD1 MN survival almost on a par with ERK inhibition, possibly by lowering JUN levels. Overall, our results indicate that mutant SOD1 activates the AP1 pathway via ERK and JNK signaling to drive neurodegeneration. It must also be noted that no single inhibitor was able to completely rescue survival of ALS MNs, suggesting that a combination of inhibitors targeting different MAPK proteins might be the best strategy to halt neurodegeneration.

How does mutant SOD1 activate MAPK signaling? Recently, it was shown that ER stress leads to activation of JNK signaling via phosphorylation of HIPK2 in the SOD1 G93A mouse model of ALS. Activation of HIPK2 and JNK closely correlated with SOD1 aggregation and cell death, suggesting a mechanism whereby increased SOD1 aggregation leads to a heightened ER stress that in turn causes cell death via activation of JNK ([@bib25]). It is possible that the ER stress may result in activation of other members of the MAPK family, including ERK, via hitherto unknown intermediary kinases. This would make the ER stress pathway an attractive target to identify ALS therapeutics. However, it must be noted that inhibiting the ER stress pathway via RNAi or pharmacological inhibition in an iPSC model of SOD1 ALS led to only modest improvement in MN survival ([@bib22]). On the other hand, FUS-R521C transgenic mice did not display any increase in ER stress markers or JNK activation in spite of showing progressive neurodegeneration ([@bib25]). Consistent with these observations, we find that MNs derived from mutant FUS iPSCs do not display activation of JNK signaling. However, these mutant FUS MNs show activation of other members of the MAPK family, namely p38 and ERK. Taken together, this suggests that the ER stress may contribute toward activating the MAPK pathway in ALS, although to a minor extent.

Muscle fasciculations are commonly observed in ALS patients and are related to underlying axonal hyperexcitability ([@bib19]). MN hyperexcitability has also been observed in vitro in a SOD1 A4V iPSC model, and inhibiting neuronal excitability via retigabine enhanced MN survival ([@bib47]). On the other hand, MNs derived from iPSCs bearing the hexanucleotide repeat expansions in *C9ORF72* showed diminished activity ([@bib6], [@bib39]). A recent study elegantly reconciled these two contradictory findings, suggesting that ALS MNs display hyperexcitability in the early stages but become hypoexcitable as the disease progresses ([@bib6]). Interestingly, neuronal firing has been shown to activate the ERK pathway, while a hyper-active ERK pathway has been shown to result in epilepsy ([@bib13], [@bib33]). This suggests a positive feedback between neuronal firing and activation of the ERK signaling cascade. Hyperexcitability in early-stage ALS MNs could result in activation of ERK signaling, thereby triggering the auto-feedback loop leading to neurodegeneration. Accordingly, inhibiting this loop either by targeting the ERK pathway or neuronal excitability promotes MN survival. It would be interesting to see whether inhibiting the ERK pathway or other members of the MAPK family would result in decreased neuronal excitability or whether inhibiting neuronal firing via retigabine reduces MAPK activity.

It must be noted that protein aggregation and an elevated ER stress have also been identified in other familial forms of ALS, including the most common mutation observed in *C9ORF72* ([@bib44], [@bib5], [@bib20]). In addition, many sporadic ALS cases commonly display TDP-43 protein inclusions in spinal MNs ([@bib28]), and these have been shown to correlate with ER stress and JNK activation ([@bib25]). Further, neuronal hyperexcitability has been established as a recurring theme across sporadic as well as familial forms of ALS ([@bib11]). Hence, it is reasonable to suppose that a combination of the ER stress mediated by TDP-43 inclusions and neuronal hyperexcitability might contribute toward activation of the MAPK pathway in other forms of ALS as well.

Due to differences in iPSC generation and MN differentiation protocols, the range and extent of phenotypes observed in ALS iPSC models are expected to vary. However, comparison across our iPSC model and other published ALS iPSC models revealed shared features among MNs bearing different ALS mutations. MNs bearing mutant SOD1 and TDP43 display decreased survival and increased apoptosis in extended cultures ([@bib3], [@bib4], [@bib22]; [Figures 2](#fig2){ref-type="fig"}B and 2D). MNs differentiated from *C9ORF72* mutant iPSCs did not display survival deficits in vitro under standard culture conditions ([@bib6]) but displayed enhanced susceptibility to cellular stressors ([@bib7], [@bib14]). Interestingly, a recent report using patient-derived iPSCs bearing C9ORF72 expansion of greater than 500 repeats displayed increased neuronal death and apoptosis in vitro ([@bib5]). Apoptotic MNs also display defects in soma size and neurite length ([@bib4], [@bib22]). Although neurite defects have not been observed in *C9ORF72* mutant MNs, interference with actin dynamics via interaction of C9ORF72 with cofilin can be expected to result in axonal defects ([@bib40]). An activated p53 response was observed in *C9ORF72* mutant MNs ([@bib26]) similar to our observation of an increased nuclear p53 in SOD1 MNs compared with the control and isogenic corrected MNs. ER stress has also been detected in MNs derived from mutant SOD1 and C9ORF72 iPSCs in parallel to the detection of SOD1 aggregation and RAN dipeptide accumulation, respectively ([@bib5], [@bib22]). On the other hand, defects in nucleocytoplasmic transport that have been observed in C9ORF72 ALS have yet to be detected in other familial forms of ALS ([@bib10], [@bib49]).

An important yet unanswered question in ALS disease pathophysiology is the targeted loss of MNs but relative sparing of non-MNs. Strikingly, we found that the AP1 complex member JUN was expressed at significantly higher levels in MNs compared with non-MNs, suggesting a role of JUN in maintaining MN homeostasis. This observation is in concordance with in situ hybridization data in human spinal cord tissue where *JUN* mRNA was found to be most abundant in MNs compared with other layers of the spinal cord, with further increases in transcript levels observed in spinal tissue of ALS patients ([@bib46]). Hence, hyperactivation of JUN in ALS MNs may disrupt the homeostatic program, thereby driving degeneration. Since the protein levels of JUN in non-MNs are low, increased levels of JUN in non-MNs may not be sufficient to prove lethal.

In summary, by combining genome correction of SOD1 mutation in patient-derived iPSCs with deep RNA-seq, we have identified signaling pathways perturbed in ALS. Further, by pharmacologically inhibiting the upregulated pathways, we find that activation of the AP1 pathway, possibly via MAPK signaling, results in neurodegeneration of MNs. Our results exemplify the power of combining genomics and genome editing with iPSC-based disease models to elucidate mechanisms of neurodegeneration and also provide phenotypic screens to search for novel molecular targets.

Experimental Procedures {#sec4}
=======================

Culture and Genome Editing of iPSCs {#sec4.1}
-----------------------------------

ALS patient-derived iPSCs bearing *SOD1 E100G/+* (ND35662) mutation as well as iPSCs derived from a healthy individual (GM23280A) were obtained from the Coriell Institute for Medical Research. Cells were maintained as colonies on human ES qualified Matrigel (Corning) in mTeSR (STEMCELL Technologies). Plasmids for the hCas9 and gRNA were obtained from Addgene and were a kind gift from the Church lab ([@bib29]). To enable efficient genome editing, we made an all-in-on vector that expressed the hCas9 from a CMV promoter and the guide-RNA targeting respective mutated loci from an U6 promoter. Mutant iPSCs were nucleofected with this vector along with a single-stranded DNA oligonucleotide homologous to 120 nt around the mutated site but bearing the wild-type sequence.

Differentiation of iPSCs into Spinal Motor Neurons {#sec4.2}
--------------------------------------------------

We adapted a recently published protocol to differentiate iPSCs into spinal MNs ([@bib30]). iPSCs were plated as colonies onto Matrigel and differentiated by treatment with neuronal differentiation media (N2B27: DMEM/F12, Neurobasal, N2 supplement 1%, B27 supplement 1%, L-glutamine 1%, ascorbic acid 5 μM, insulin 20 μg/mL) supplemented with SB431542 (80 μM), CHIR9921 (3 μM), and LDN8312 (0.2 μM) from day 0 until day 4. Cells were caudalized by treatment with 0.1 μM retinoic acid starting at day 2 and ventralized with 1 μM purmorphamine starting at day 4 and continued until day 10. At day 10, OLIG2-positive MN progenitors were re-plated onto poly-D-lysine/laminin-coated wells and differentiated by treating the cells with N2B27 media supplemented with brain-derived neurotrophic factor 20 ng/mL, GDNF 10 ng/mL, and DAPT 10 μM. DAPT treatment was stopped at day 15, and neuronal cultures were pulsed with mitomycin at a dose of 10 μg/mL for 1 hr to prevent further proliferation of any undifferentiated progenitors. Neuronal cultures were maintained until day 30 by changing the media every other day.

Electrophysiology {#sec4.3}
-----------------

For multi-electrode array (MEA) recordings, progenitors derived from GM23280A iPSCs were plated directly on an MEA and differentiated as described above. Extracellular electrophysiological recordings of D34 neurons were performed in neuronal growth medium using a 60-channel MEA platform (MEA1060, Multichannel Systems) as previously described ([@bib8]). MC_Rack software (Multichannel Systems) was used to acquire extracellular signals that were high-pass filtered at 300 Hz and low-pass filtered at 3 kHz with second-order Butterworth filters. Signals were sampled at 25 kHz. Action potentials or spikes were detected using voltage thresholds that were set at 6 SDs away from the channel\'s baseline noise. Electrophysiological data were imported into MATLAB using the Neuroshare API library ([www.neuroshare.org](http://www.neuroshare.org){#intref0010}). Optical stimulation was performed by the system setup as previously described ([@bib18]). A 500 mW 473 nm blue laser beam was expanded and projected onto a reflective spatial light modulator (SLM, Holoeye Photonics), with a resolution of 1920 × 1080 pixels. The SLM received input from the computer to produce reflective patterns. The generated light patterns were then projected onto the MEA culture through the objective lens of an inverted microscope (Nikon Ti-E). The final light intensity at the MEA culture is ∼4.5 mW/mm^2^. Transistor-transistor logic pulses were sent to control the beginning and end of laser stimulus precisely.

Calcium Imaging {#sec4.4}
---------------

GM23280A iPSC-derived D14 MNs were plated on glass bottom imaging dishes and infected with lentiviral particles expressing GCaMP6 for 6 hr, washed, and the media replaced with neuronal media as described above. At D21 of differentiation, cortical neurons obtained from embryonic day 18 (E18) rat pups were plated onto the MN monolayer. Cortical tissue was dissected from rat pups as described previously ([@bib8]). Cortical MN co-cultures were allowed to develop for 2 weeks before recording the GCaMP6 fluorescence intensity. After GCaMP6 recordings, co-cultures were treated with the Ca^2+^ indicator Fluo-4, incubated for 15 min, and fluorescence intensities were recorded for the same field.

MN Survival Assay {#sec4.5}
-----------------

Day 10 MN progenitors were plated on poly-D-lysine/laminin-coated 96-well plates at a density of 5,000 cells per well and differentiated into neurons. Cells were immunostained at day 30 ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) and images were captured on the Operetta imaging system (PerkinElmer) in an automated fashion. MNs and non-MNs were detected based on ISL1 and TUJ1 staining and quantified by the Columbus software using standard pipelines. Cells were cultured further for 14 days, immunostained, and counted as above. Counts at day 44 were normalized to those obtained at day 30. Motor neuronal soma and neurites were detected by first identifying ISL1+ nuclei and then demarcating soma and neuronal processes using Columbus pipelines. Apoptotic cells at day 37 were detected using the CellEvent Caspase 3/7 green detection reagent (Thermo Fisher) according to the manufacturer\'s instructions. The reagent was added to live neurons and incubated for 30 min, then counterstained with the nuclear dye Hoechst 33542 (Molecular Probes).

RNA-Seq and Analysis {#sec4.6}
--------------------

RNA was extracted from day 30 neuronal cultures as described above. Sequencing libraries were generated from 1 μg of RNA using the NEBnext Ultra kit (NEB) according to the manufacturer\'s instructions and sequenced on an Illumina HiSeq instrument. Raw reads were mapped to the human genome hg19 using bwa, and only reads mapping to unique locations retained. The DESeq2 R package ([@bib27]) and custom R scripts were used to analyze the mapped reads and generate a list of differentially expressed genes sorted by the statistical score. GSEA was performed using the GSEA software (<http://software.broadinstitute.org/gsea/index>).

Immunofluorescence {#sec4.7}
------------------

For immunostaining, cells were fixed with 4% paraformaldehyde, permeabilized with ice-cold methanol for 5 min, and washed with PBS containing 10% serum for 1 hr at room temperature. Cells were incubated with primary antibodies ([Table S2](#mmc1){ref-type="supplementary-material"}) diluted into PBS containing 10% serum and incubated overnight at 4°C. Next day, the cells were washed and incubated with Alexa-Fluor conjugated secondary antibodies (Molecular Probes) for 45 min at room temperature, and nuclei were stained with Hoechst 33542 (Molecular Probes).

Western Blot {#sec4.8}
------------

Cell lysates were separated on 12% SDS-PAGE gels, and proteins were transferred onto polyvinylidene fluoride (PVDF) membranes. Membranes were blocked with 5% milk in TBST (25 mM Tris \[pH 8.0\], 150 mM NaCl, 0.05% Tween 20) and probed with corresponding primary antibodies against specific proteins ([Table S2](#mmc1){ref-type="supplementary-material"}). Horseradish-peroxidase-conjugated secondary antibodies (SCBT) were used to detect primary antibodies, and proteins were visualized by chemiluminescence (Nacalai Tesque). The SOD1 soluble fraction (TBS + 1% Triton X-100) and insoluble fraction (TBS + 1% Triton X-100 + 5% SDS) were transferred to PVDF membranes and probed with an anti-SOD1 antibody.

qRT-PCR {#sec4.9}
-------

RNA was extracted with TRIzol reagent (Invitrogen) and reverse transcribed using random hexamers and the high-capacity reverse transcription system from Applied Biosystems. PCR was performed using the SYBR GREEN PCR Master Mix from Applied Biosystems. The target gene mRNA expression was normalized to the expression of GAPDH, and relative mRNA fold changes were calculated by the ΔΔCt method. Primer sequences have been included in [Table S3](#mmc1){ref-type="supplementary-material"}.
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![Generation of Isogenic Controls and Spinal Motor Neurons\
(A) Guide-RNA design and targeting of the SOD1 mutant allele. Genomic sequence around the SOD1 mutant allele is shown with the reference and mutant allele (bold and underlined). The guide RNA is shown aligned with the mutant locus with the PAM recognition sequence highlighted in red.\
(B) Chromatogram showing CRISPR-Cas9-mediated genome correction of *SOD1*+/E100G (designated E100G) to *SOD1*+/+ (designated E100E). The inverted yellow triangles indicate the heterozygous point mutation A/G (upper panel) and the corresponding homozygous A/A genotype (lower panel) upon genome correction.\
(C) Schematic illustrating differentiation of iPSCs into spinal MNs. Smadi, dual SMAD inhibition using SB431542 + LDN193189; Chir, CHIR99021; RA, retinoic acid; Pur, purmorphamine.\
(D) Differentiation of MNs from iPSCs. Neurons were immunostained for ISL1 (red) and TUJ1 (green). Nuclei were stained with Hoechst 33452 (blue). E100G, *SOD1*+/E100G; E100E, *SOD1*+/+; 80a, iPSCs from a healthy individual used as a control.\
(E) Quantitation of MNs staining positive for CHAT. Neurons were immunostained for ISL1 (red) and CHAT (green). (n = 3, error bars indicate SEM).\
(F) Left: Representative fluorescent image of the MEA to visualize eYFP expression. MNs co-expressed Channel Rhodopsin-2 (ChR2) with eYFP. The blue rectangle highlights the area stimulated with a 473 nm laser at 5 Hz (50% duty cycle) for 2 s. Right: Raster plots of action potentials recorded extracellularly from active electrodes of the MEA. In total, 42 active channels containing at least two spikes were plotted. The electrode adjacent to the optically stimulated neuron (blue rectangle in the left panel) detected spiking activity synchronized to the 5 Hz stimulus protocol. Inset: enlarged plot showing light-evoked spikes with blue background indicating when the light was on (see also [Figure S1](#mmc1){ref-type="supplementary-material"}).\
All scale bars indicate 50 μM.](gr1){#fig1}

![Modeling ALS In Vitro Using iPSC-Derived MNs\
(A) Schematic depicting the disease modeling protocol.\
(B) ALS MNs display a significant loss in survival compared with control MNs when plated at low density. Correction of the ALS-associated mutation rescues the observed phenotype. MNs were identified as ISL1+/TUJ1+ neurons.\
(C) ALS or control non-MNs, identified as ISL1-/TUJ1+, do not display a survival deficit.\
(D) ALS MN cultures at day 37 display a higher percentage of cells undergoing apoptosis as measured by cleaved caspase activity.\
(E) Quantitation of soma size for day 44 MNs. Soma size was normalized to control day 44 MNs.\
(F) Quantitation of maximum neurite length for day 44 MNs. Data were normalized to control day 44 MNs.\
(G) Quantitation of neurite tree length for day 44 MNs. Data were normalized to control day 44 MNs.\
(H) Immunofluorescence intensities of nuclear p53 in day 30 MNs. Values were normalized to control MNs. Data from three independent replicates were pooled to generate the boxplot and estimate the p values.\
(I) qRT-PCR data to measure the *sXBP1:XBP1* ratio, an indicator of ER stress in day 37 MNs. Ratios were normalized to data from control MNs.\
(J) Western blot assay showing levels of detergent-soluble and insoluble SOD1 in ALS and control MN lysates at day 30.\
(B--I) n = 3, error bars indicate SEM; ^∗^p \< 0.01; n.s., not significant; p values were estimated using two-tailed Student's t test. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![RNA-Seq Analysis Identifies Signaling Pathways Dysregulated in ALS MNs\
(A) Dendrogram showing clustering of diseased and isogenic corrected samples based on transcriptional changes detected by RNA-seq. The number of genes differentially regulated in ALS MNs compared with isogenic control MNs are displayed.\
(B) GSEA detected gene sets activated and repressed in SOD1 MNs.\
(C) qRT-PCR to confirm activation of genes identified via RNA-seq. n = 3, error bars indicate SEM; ^∗^p \< 0.01; p values were estimated using two-tailed Student's t test.\
(D) Network analysis of gene sets activated in SOD1 MNs. Data were obtained from the STRING database ([@bib43]).](gr3){#fig3}

![Identification of Pathways Driving Neurodegeneration in ALS MNs\
(A) Quantitation of ISL1-positive mutant SOD1 MNs after treatment with small-molecule inhibitors of the indicated pathways. n = 3, error bars indicate SEM; ^∗^p \< 0.01; p values were estimated using two-tailed Student's t test.\
(B) Western blot analysis showing increased levels of phosphorylated ERK and JNK in mutant SOD1 MNs. Percentages relative to respective isogenic controls are displayed below each blot. Values underlined indicate increased levels of the detected proteins. Lysates from two independent replicates were pooled and assayed in triplicate. Data indicate means ± SEM.\
(C) Boxplot displaying nuclear intensities of p-JUN in ALS mutant MNs normalized to the respective isogenic controls. Data from three independent replicates were pooled to generate the boxplot and estimate the p values. ^∗^p \< 0.01; p values were estimated using two-tailed Student's t test.\
(D) Boxplot displaying nuclear intensities of p-JUN in mutant SOD1 MNs and non-MNs as well as isogenic control MNs and non-MNs. Data from three independent replicates were pooled to generate the boxplot and estimate the p values. ^∗^p \< 0.01; p values were estimated using two-tailed Student's t test.\
(E) Schematic depicting pathways activated by mutant SOD1 that drive neurodegeneration.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Mutant FUS MN Display Activated MAPK Signaling\
(A) Chromatogram showing correction of homozygous FUS *H517Q/H517Q* iPSCs (designated H517Q) to heterozygous FUS*+/H517Q* (designated H517H). The yellow triangle indicates the position of the homozygous point mutation G/G (upper panel) and the corresponding heterozygous C/G genotype (lower panel) upon genome correction.\
(B) Isogenic corrected iPSCs display a normal karyotype.\
(C) Mutant and isogenic corrected iPSCs differentiate into ISL1+/TUJ1+ MNs as well as ISL1+/CHAT+ MNs with similar efficiencies.\
(D) Western blot assay displaying activated p38 and ERK in mutant FUS MNs compared with the isogenic controls. JNK was not found to be activated in mutant FUS MNs. Lysates from two independent replicates were pooled and assayed in triplicate. Data indicate means ± SEM.\
All scale bars indicate 50 μM.](gr5){#fig5}
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